Anavex Life Sciences Corp. AVXL R2KR3KPHARMA
Company Overview
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -87.41% |
| 6 Months: | -60.18% |
| 3 Months: | -46.80% |
| 1 Month: | -43.16% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)23.01 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 87.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 23 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AVXL Anavex Life Sciences Corp. R2KR3KPHARMA | 1.33 | -9.50 | $123.29M | 0.00% | -54.15% | -12.80% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.58M | 12.42M | 14.31M | 11.48M | 6.78M |
| Operating Income | -125.98K | -309.61K | -1.02M | -998.83K | -770.68K | -858.34K | -1.51M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.72M | -11.52M | -12.46M | -15.38M | -14.19M | -13.53M | -11.38M | -12.62M | -14.60M | - | -13.58M | -12.42M | -14.31M | -11.48M | -6.78M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.58M | -12.42M | -14.31M | -6.49M | -6.78M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.11M | -11.20M | -13.24M | -9.83M | -5.66M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -124.00K | 0 | - | - | - | 18.00K |
| Net Income | -151.92K | 358.64K | -1.02M | -1.01M | -786.72K | -1.72M | -4.24M | -3.95M | -2.03M | -2.24M | -3.15M | -1.55M | -3.61M | -4.06M | -4.75M | -2.85M | -6.92M | -7.25M | -6.52M | -6.59M | -7.24M | -6.49M | -7.86M | -8.16M | -10.18M | -10.88M | -10.44M | -12.37M | -12.97M | -13.11M | -11.28M | -8.62M | -10.55M | -12.21M | - | -12.11M | -11.20M | -13.24M | -9.83M | -5.68M |
| Diluted EPS | -0.01 | -0.01 | -0.03 | -0.03 | -0.06 | -0.12 | -0.22 | -0.12 | -0.06 | -0.06 | -0.08 | -0.04 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.17 | -0.17 | -0.14 | -0.11 | -0.13 | -0.14 | - | -0.14 | -0.13 | -0.16 | -0.11 | -0.06 |
| R&D Expense | 39.02K | 5.18K | 118.15K | 265.01K | 318.62K | 407.15K | 799.46K | 1.16M | 1.09M | 1.16M | 2.04M | 2.49M | 2.30M | 2.69M | 3.25M | 3.00M | 5.71M | 6.08M | 5.76M | 6.35M | 6.05M | 6.73M | 7.93M | 6.72M | 8.96M | 8.66M | 8.60M | 9.27M | 12.07M | 11.31M | 10.28M | 8.68M | 9.73M | 11.81M | - | 10.45M | 9.89M | 9.96M | - | 4.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2005 | Sep 2006 | Sep 2007 | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.99M | 55.74M | 52.80M | 51.37M |
| Operating Income | - | - | - | - | - | -5.65M | -6.18M | -4.32M | -2.14M | -2.97M | - | - | - | - | - | -31.09M | - | -50.99M | -55.74M | -52.80M | -51.37M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -47.62M | -46.54M | -43.00M | -46.38M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 964.00K | 0 | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -47.62M | -47.51M | -43.00M | -46.38M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 268.00K | 358.00K | 7.00K | 0 | - |
| Net Income | -91.62K | -25.53K | -1.58M | -5.35M | -5.50M | -8.78M | -7.31M | -8.30M | -3.70M | -9.97M | -12.11M | -14.74M | -13.46M | -17.25M | -26.29M | -26.28M | - | -47.98M | -47.51M | -43.00M | -46.38M |
| Diluted EPS | - | - | - | - | - | -0.41 | -0.29 | -0.29 | -0.12 | -1.02 | -0.65 | -0.42 | - | - | - | - | - | -0.62 | -0.60 | -0.52 | -0.54 |
| R&D Expense | - | - | - | - | - | 2.73M | 2.60M | 2.65M | 263.85K | 732.39K | 2.27M | 7.25M | 10.67M | 13.34M | 22.26M | 25.23M | 32.98M | 37.92M | 43.72M | 41.84M | 37.59M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2004 | Sep 2005 | Sep 2006 | Sep 2007 | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | 329.85K | 203.04K | 13.15K | 393.45K | 7.35M | 15.47M | 9.50M | 27.84M | 26.21M | 25.33M | 34.54M | - | 152.71M | 154.39M | 135.57M | 103.81M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 152.71M | 154.39M | 135.57M | 103.81M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | - | - | - | 9.19M | 27.44M | 22.93M | 22.19M | 29.25M | - | 149.16M | 151.02M | 132.19M | 102.58M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.19M | 2.71M | 2.45M | 809.00K |
| Total Liabilities | - | - | - | - | - | - | 3.29M | 1.35M | 2.89M | 2.86M | 7.16M | 2.66M | 3.19M | 3.58M | - | 5.04M | 7.31M | - | 10.21M | 12.53M | 15.30M | 8.95M |
| Current Liabilities | - | - | - | - | - | - | - | - | 2.89M | 1.95M | 1.44M | 2.66M | 3.19M | 3.58M | 3.88M | 5.04M | - | - | 10.21M | 12.53M | 15.30M | 8.95M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | 5.72M | 332 | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 25.61K | -26.02K | -15.51K | -462.50K | -2.29M | -3.86M | -2.96M | -1.14M | -2.88M | -2.46M | 192.63K | 12.81M | 6.31M | 25.88M | 22.32M | 20.29M | 27.24M | - | 142.49M | 141.85M | 120.26M | 94.87M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 77.94M | 82.07M | 84.80M | 86.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.59M | -3.80M | -1.69M | -777.57K | -2.66M | -4.23M | -9.24M | -9.02M | -12.58M | -18.53M | -21.29M | - | -24.24M | -27.79M | -30.81M | -39.04M |
| Investing Cash Flow | -3.31K | 0 | 0 | 0 | -3.02K | - | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | 4.51M | 3.67M | 1.57M | 1.11M | 9.58M | 12.26M | 3.13M | 27.27M | 8.07M | 17.78M | 28.35M | - | 21.29M | 29.65M | 11.97M | 9.43M |
| Capital Expenditure | - | - | - | - | -3.02K | - | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | -2.66M | - | - | - | - | - | - | - | -24.24M | -27.79M | -30.81M | -39.04M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -2.95M | 1.87M | -18.84M | -29.61M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2005 | Sep 2006 | Sep 2007 | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 352.1% | 164.6% | 341.6% | 233.5% | 142.6% | 296.7% | 639.6% | 288.7% | 150.2% | -5,175.0% | -94.5% | -233.6% | -52.0% | -77.3% | -129.6% | -96.5% | - | -33.7% | -33.5% | -35.8% | -48.9% |
| ROCE % | - | - | - | - | - | - | - | 150.3% | 137.1% | -50.2% | - | - | - | - | - | - | - | -35.8% | -39.3% | -43.9% | -54.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.69% | 8.06M | $12.00M |
| 2 | Vanguard Capital Management LLC | 4.37% | 4.05M | $6.04M |
| 3 | Two Sigma Investments, LP | 3.29% | 3.05M | $4.54M |
| 4 | Geode Capital Management, LLC | 2.60% | 2.41M | $3.59M |
| 5 | State Street Corporation | 2.07% | 1.92M | $2.86M |
| 6 | Federated Hermes, Inc. | 1.16% | 1.07M | $1.60M |
| 7 | AQR Capital Management, LLC | 1.04% | 963.01K | $1.43M |
| 8 | Vanguard Portfolio Management LLC | 1.02% | 948.63K | $1.41M |
| 9 | Summit Financial, LLC | 0.98% | 909.43K | $1.36M |
| 10 | Goldman Sachs Group Inc | 0.96% | 890.63K | $1.33M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AVXL
Anavex Life Sciences Corp. (AVXL) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE1QdndpRFVWRGxpU2lQX0dYYmxWd3h4cGRiTnNkZDRjR1ktTzEtZi0zcTVOTFBaN0NTUGhDaDJxTzhKNFpHV1hZOHhzTV85dkZNd3c?oc=5" target="_blank">Anavex Life Sciences Corp. (AVXL) stock price, news, quo…
Anavex Life Sciences Corp. (AVXL) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE5pMjFsb09WY3V5d3QtekY2T1pqanYyMFg1Sk1wT3A3RjI3Wnp2MmxEcGxUV0FYRGR6X0pPTmN4NUZfSkRlNXVQWXdLbWpJMmU2Q3c?oc=5" target="_blank">Anavex Life Sciences Corp. (AVXL) Stock Price, News, Quo…
The FDA cleared Anavex's application to test its drug in people with Fragile X - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPdUxjM1B2MzdKSmtaVFN2QzRUVVAxN0xKRk1GQUVzbzFZa0xkN0JQb245ckFTVHF3QlBsaDhjVGljOU9vaTg0TVdoeVFFeVYtZTdLNEtuXzlaaDhJU0tyVHpzWnpTWVBZZ2dlWXVBTm1Lekl6THJ6WXZnTUNjRFQtTW5ldlljajVQS3B6R2…
Anavex: After The EU Said No, The FDA Path Looks Long And Expensive - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOb0pmYW5DbkJ1N251bUE2bVlsREFKQmZBLXFkSDBJdE9faWphZWR1UG9DQW5EZmFDTGE3Vkw1djRTY2xCTDdKVWhMV0RkR1Z1VktKTk1DWERmTHIxZWZHbmdjdEUwbVNwSVZCZS1QclFXY09tZ19na0kwWXR2NzVEb3h0VWluZlBfOENXNX…
Robbins LLP Urges AVXL Stockholders Who Lost Money Investing in A - The National Law Review
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNbTVXWU9SUW8ySVVjZWh1cUtwMk51MEpzWjRQSWVBSC1uMmtKQWlKWWg1aWw0SXhwRk9LU3RxMG5uLXNsTUV4bkw0WURwU1ltUEZBOFFVUFRGWHZOZXlwTHFPUmszVTlpOGtWbWxxVkVLQWhGQUpheUVWUEszVnlCOF8wQXRXSTQtWll3Zl…
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 30, 2026 in Anavex Life Sciences Corp. Lawsuit - AVXL - Morningstar
<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxOclFaTG1MTENVblBwai1pNVdRN1Y2WXpuTFB6bERGeVRwdy1Rb0FXWXBkckhsei1DWktoVTk2NWFhZmROTmtvbjNKRFVOOE5iekNlS3BKaGpOMWdKaEx6UDNuOUtqTmJUcVIxRmNUZkFWdkdJem5YWWJVV2ZldUJqTEVaLUV4X3gxVzNYRX…
AVXL — Frequently Asked Questions
What is the current share price of Anavex Life Sciences Corp. (AVXL)?
As of 2026-10-23 16:27 PDT, Anavex Life Sciences Corp. (AVXL) trades at $1.33 on NasdaqGS. Its 52-week range is $1.25 to $10.56.
What is the market capitalisation of AVXL?
Anavex Life Sciences Corp. (AVXL) has a market capitalisation of $123.29M on NasdaqGS.
What is the P/E ratio of AVXL?
AVXL trades at a trailing price-to-earnings (P/E) ratio of -9.50. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.23.
What is the return on equity (ROE) of AVXL?
AVXL has a return on equity (ROE) of -12.80%. Its return on capital employed (ROCE) is -54.15%.
Is AVXL a good stock to buy?
This page provides a data-driven analysis of Anavex Life Sciences Corp. (AVXL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.